US3137631A - Encapsulation in natural products - Google Patents

Encapsulation in natural products Download PDF

Info

Publication number
US3137631A
US3137631A US856379A US85637959A US3137631A US 3137631 A US3137631 A US 3137631A US 856379 A US856379 A US 856379A US 85637959 A US85637959 A US 85637959A US 3137631 A US3137631 A US 3137631A
Authority
US
United States
Prior art keywords
water
water insoluble
particles
albumin
encapsulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US856379A
Inventor
Soloway Saul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faberge Inc
Original Assignee
Faberge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faberge Inc filed Critical Faberge Inc
Priority to US856379A priority Critical patent/US3137631A/en
Application granted granted Critical
Publication of US3137631A publication Critical patent/US3137631A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/08—Simple coacervation, i.e. addition of highly hydrophilic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Definitions

  • Carbonless Carbon Paper can be made by coating the under side of one sheet of paper with capsules containing a potential color forming reactant. The top side of a second sheet is impregnated with capsules containing the developing reagent. The application of pressure to the pair of sheets in contact causes both types of capsules to rupture, thereby releasing the contents with consequent color development.
  • Urea-aldehyde prepolymers are disclosed as being especially suitable for use in such a process but Water soluble resins forming compounds capable of forming melamine, epoxy, thiourea, polyamide, dicyanodiamidealdehyde resins are likewise disclosed as being suitable.
  • the water insoluble organic liquids were disclosed as being encapsulated in a plurality of concentric shells made of the same or different resin-forming compounds or in a composite shell composed of a plurality of resin-forming compounds.
  • the water insoluble organic liquids could be encapsulated in a water insoluble composite shell derived conjointly from water soluble heat denaturable proteins and water soluble compounds which form cross-linked synthetic resins.
  • the objectives set out above, and other valuable objectives are obtained by encapsulating water insoluble organic liquids in water insoluble shells derived from water soluble heat denaturable proteins.
  • they are dispersed in an aqueous solution of the water soluble proteins and the proteins are then denatured in the presence of the dispersed particles of water insoluble organic liquids to thereby encapsulate the particles in a water insoluble solid protein shell.
  • the proteins are denatured by the application of heat but they can be denatured by use of other kinds of energy as by use of ultraviolet light or ultrasonic sound or by chemicals as by acid or alkali denaturing.
  • water insoluble organic liquids may be encapsulated in shells derived from water soluble heat denaturable proteins alone, known cross-linking agents for proteins such as formaldehyde, glyoxal and the like may be used to react with the proteins during the formation of the shell, or after the shell is formed, to impart increased stability to the capsule.
  • cross-linking agents for proteins such as formaldehyde, glyoxal and the like may be used to react with the proteins during the formation of the shell, or after the shell is formed, to impart increased stability to the capsule.
  • the dissolved water soluble proteins normally have some aflinity for the diluted dispersion of globules of water insoluble organic'liquids and, therefore, tend to concentrate at the interface between the globules and the continuous aqueous phase. In this way, the proteins form a coating around the globules and, when denatured, form a solid water insoluble capsule therearound.
  • emulsifying agents which are usually of an oily or fatty nature, may be used to facilitate the formation of an aqueous dispersion.
  • Egg albumin has proven especially valuable as a source of heat denaturable protein for, among other things,
  • the egg albumin is a good emulsifying agent and the ta water bath. At 65 C.
  • water insoluble organic liquid can be easily dispersed in the aqueous body'in the presence of egg albumin by mechanical agitation with a conventional high speed mixer.
  • Other water soluble and heat denaturable proteins I suitable for use in the process of this invention include blood, other albumins, blood plasma, globulin, myosin,
  • the water soluble proteins maybe effectively and economically denatured by the application of heat tothereby form a I water insoluble solid shell around the water insoluble liquid.
  • other forms of energy or chemical means may be'used to denature the proteins and render them water insoluble as by the use of ultraviolet light, ultrasonic sound or by the use of chemicals such as acid or alkali denaturants.
  • the present invention relates to a process for encapsulating, or coating, particles 'of water insoluble organic liquids'withdenatured and water a I insolubilized proteins and to. the resulting encapsulated I product.
  • the invention' relates to a process involving dispersing particles of a water insoluble organic compound in anaqueous solution of a water soluble heat denaturable protein-thereby applying to and absorbing on the surfaces of the dispersed particles the heat denaturable protein and denaturing the protein on the surfaces of the' particles until it'becornes substantially water insoluble, i.e., cross-linked.
  • the dispersion of the water insoluble organic liquid in the aqueous media may be facilitated by using I a water soluble thickening agent, or an agent imparting colloidality to the media.
  • I a water soluble thickening agent
  • Compounds found very useful as thickening agents include methyl cellulose, hy-
  • these colloids are water soluble, they also have some affinity for the Water insoluble organic liquid.
  • ,Thus thesefcolloids fa cilitate the formation ofv an aqueous dispersion of the organic liquid and have a tendency to concentrate at the interface between the dispersed Water insoluble organic liquid and the continuous aqueous phase. In this way,
  • EXAMPLE 6 Encapsulation a Mixture of Essential Oils in Urea- F ormaldelzyde, Albumin and Barium Sulfate Fifty (50) ml. of water was used to dissolve grams of urea, 12.5 grams of 37% aqueous formaldehyde, and 2.5 grams of sodium sulfate. Ten grams of the perfume oil of Example 5 and 1 gram of a mixture of mono and dilauryl phosphates were stirred into the aqueous solution while stirring with a stirrer rotating at 200-300 r.p.m. Then 5 grams of egg albumin in 25 ml. of water was added, and the stirring at 200-300 r.p.m. continued for a half hour.
  • Colloidal silica or powdered titanium dioxide could be added, at this point in the procedure, in lieu of barium chloride.
  • EXAMPLE 7 Encapsulation of Normally Solid Volatile Compounds
  • 50 grams of a 10% aqueous egg albumin solution was added and the stirring continued for an equal period.
  • the resulting suspension of capsules may be washed free of mother liquid or used as such for spray-drying, brush or blade application to the surface of paper or other nonwoven or woven fibrous materials.
  • This preparation can be made odor free by air-drying the filtered, or centrifuged, capsules overnight in an oven kept at 50 to 60 C.
  • the principles of this invention can be applied to the encapsulation of any ingredient which has a greater affinity for the water insoluble organic liquid than it has for Water.
  • the water insoluble organic compound is an oil any ingredient may be kept in dispersion in the dispersed oil phase which is more lipophilic than hydrophilic.
  • Predominantly lipophilic emulsifiers could be used to assist in the dispersion of the substances in the oil phase.
  • the same principle may be used to encapsulate solids which are insoluble both in the oil phase and in the water.
  • a liquid phase process for encapsulating a water insoluble organic liquid which comprises dispersing finely divided particles of said liquid and a solution of egg albumin in a body of water, heat denaturing said albumin until it forms a substantially water insoluble denatured egg albumin coating around said particles while said particles are dispersed in said body of water thereby encapsulating the particles in a solid shell and separating the encapsulated particles from the body of water.
  • a liquid phase process for encapsulating a water insoluble organic liquid which comprises dispersing finely divided particles of said liquid and a solution of a plurality ofwater soluble cross-linking resin-forming compounds in a' body ofwater, at least one of said resin-forming compounds being a heat denaturable albumin, denaturing said albumin by the application of heat and polymerizing any remaining resin-forming compounds until they deposit solution of a water soluble heat denaturable albumin in v a body of Water, applying heat to said body of water untilsaid albumin deposits a substantially water insoluble heat denatured albumin coating around said particles while said particles are dispersed in said body of Water thereby encapsulating particles in' a solid shell and separating the encapsulated particles from the body Of'WZlIGI".
  • Finely divided particlesof a perfume oil encapsulated in a solid shell of'a heat denatured egg albumin 8. Finely divided particlesof a perfume oil encapsulated in a solid shell of'a heat denatured egg albumin.
  • a fibrous tissue having incorporated therein finely divided particles of a Water insoluble but Volatile liquid encapsulated in a heat denatured alb umin shell derived from, a Water soluble albumin.

Description

3,137,631 EN CAPSULATION 1N NATURAL PRODUCTS Saul Soloway, New Rochelle, N.Y., assignor, by mesne assignments, to Faberge, Inc., Ridgefield, NJL, a corporation of Delaware No Drawing. Filed Dec. 1, 1959, Ser. No. 856,379 11 Claims. (Cl. 167-83) This invention relates to encapsulating water insoluble organic liquids and the resulting products.
Those liquids, compounds or mixtures, which have appreciable vapor pressures or which are subject to chemical change by reaction with some atmospheric constituent, may be protected from volatilization or reaction with the environment by enclosure in inert capsules. Solids, having similar properties, may be dissolved in appropriate liquids and then encapsulated as solutions. Some of the volatile essential oils of commerce which could be encapsulated to advantage for applications to be discussed later are: oils of lemon, orange, anise, pine, almond, thyme, rose, jasmine and citronella. In fact one might include all the oils used in the perfume, flavor, food and allied industries. Specific types of compounds such as aldehydes, olefins, acetylenes, mercaptans, amines, ethers and phenols are readily protected against autoxidation by encapsulation. Protection of oxygen sensitive compounds without the use of an anti oxidant is particularly desirable for the preservation of animal fats, vegetable oils and vitamins such as A, E, and C. The general use of anti oxidants in these instances is viewed as that of a necessary contaminant.
It is often desirable to envelop substances, which may or may not be stable, in capsules which are frangible. Such capsules may be integrated into a fabric, woven or non-woven, so that the application of pressure will release the material. This concept constitutes a novel Way of dispensing perfume and certain types of medication. The encapsulation of such voltile compounds as menthol, camphor, pine oil, oil of eucalyptus, etc. offers a most convenient mode of dispensing alleviants for respiratory disease.
The separate encapsulation of two or more potential reactants offers many possibilities. Carbonless Carbon Paper can be made by coating the under side of one sheet of paper with capsules containing a potential color forming reactant. The top side of a second sheet is impregnated with capsules containing the developing reagent. The application of pressure to the pair of sheets in contact causes both types of capsules to rupture, thereby releasing the contents with consequent color development.
For the reasons given above, many attempts have been made to encapsulate organic substances which are in soluble in Water and are liquid at temperatures at which water is liquid. (Such substances are hereinafter called water insoluble organic liquids.) For example, efforts have been made to encapsulate such substances in gels or encompass them in waxes. Such efforts have not been adequately successful because of rapid leakage through the gel and structural weakness of the wax. Waxes are also readily dissolved by most organic oils and hence are only limited to use for encapsulating polar liquids.
' It is a principal object of this invention to overcome, or at least abate the drawbacks heretofore associated with encapsulating water insoluble organic liquids. It is a special object of this invention to provide an encapsulating process which can be carried out at the mild temperature at which water is liquid. It is a special object of this invention to encapsulate volatile substances such as perfume coils or substances which favorably affect respiration. Other objects and features of the invention A United States Patent will become apparent from the more detailed description of the invention which follows.
In my copending application Serial No. 846,535, filed October 15, 1959, now abandoned, it was disclosed that the aforesaid objectives can be obtained by encapsulating water insoluble liquids, such as mentioned above, in solid shells of cross-linked synthetic resins. These encapsulating cross-linked synthetic resin shells, as is known, are water insoluble and are insoluble in usual organic solvents. In order to encapsulate the water insoluble organic liquids in the synthetic crosslinked resin shells, the water insoluble organic liquid was dispersed in an aqueous solution of compounds capable of forming cross-linked synthetic resins by the application of heat or catalyst or both and then the resinforming compounds were polymerized in the presence of the dispersed Water insoluble liquids to thereby encapsulate them. Urea-aldehyde prepolymers are disclosed as being especially suitable for use in such a process but Water soluble resins forming compounds capable of forming melamine, epoxy, thiourea, polyamide, dicyanodiamidealdehyde resins are likewise disclosed as being suitable.
In special embodiments of that invention, the water insoluble organic liquids were disclosed as being encapsulated in a plurality of concentric shells made of the same or different resin-forming compounds or in a composite shell composed of a plurality of resin-forming compounds. In a particular embodiment of that invention, it was disclosed that the water insoluble organic liquids could be encapsulated in a water insoluble composite shell derived conjointly from water soluble heat denaturable proteins and water soluble compounds which form cross-linked synthetic resins.
In accordance with this invention, the objectives set out above, and other valuable objectives, are obtained by encapsulating water insoluble organic liquids in water insoluble shells derived from water soluble heat denaturable proteins. In order to encapsulate the water insoluble organic liquids, they are dispersed in an aqueous solution of the water soluble proteins and the proteins are then denatured in the presence of the dispersed particles of water insoluble organic liquids to thereby encapsulate the particles in a water insoluble solid protein shell. In an important method of practicing the invention, the proteins are denatured by the application of heat but they can be denatured by use of other kinds of energy as by use of ultraviolet light or ultrasonic sound or by chemicals as by acid or alkali denaturing. Although valuable substances in capsule form may be obtained by encapsulating the Water insoluble organic liquids in shells derived from water soluble heat denaturable proteins alone, known cross-linking agents for proteins such as formaldehyde, glyoxal and the like may be used to react with the proteins during the formation of the shell, or after the shell is formed, to impart increased stability to the capsule. By following the process hereof water insoluble organic liquids are encapsulated in a substantially impermeable shell of a denatured denaturable protein.
While no theory is necessary to an understanding of this invention, it is felt that the dissolved water soluble proteins normally have some aflinity for the diluted dispersion of globules of water insoluble organic'liquids and, therefore, tend to concentrate at the interface between the globules and the continuous aqueous phase. In this way, the proteins form a coating around the globules and, when denatured, form a solid water insoluble capsule therearound.
If desired, known emulsifying agents, which are usually of an oily or fatty nature, may be used to facilitate the formation of an aqueous dispersion.
Egg albumin has proven especially valuable as a source of heat denaturable protein for, among other things,
the egg albumin is a good emulsifying agent and the ta water bath. At 65 C.
water insoluble organic liquid can be easily dispersed in the aqueous body'in the presence of egg albumin by mechanical agitation with a conventional high speed mixer. Other water soluble and heat denaturable proteins I suitable for use in the process of this invention include blood, other albumins, blood plasma, globulin, myosin,
glutelin, excelsin, edestin, arachin, casein and like water soluble proteins and their mixtures which become denatured by heating. I t I In the encapsulating process disclosed above, the water soluble proteins maybe effectively and economically denatured by the application of heat tothereby form a I water insoluble solid shell around the water insoluble liquid. On the other hand, other forms of energy or chemical means may be'used to denature the proteins and render them water insoluble as by the use of ultraviolet light, ultrasonic sound or by the use of chemicals such as acid or alkali denaturants.
Thus, broadly considered, the present invention relates to a process for encapsulating, or coating, particles 'of water insoluble organic liquids'withdenatured and water a I insolubilized proteins and to. the resulting encapsulated I product. In accordance with a more limited aspect of the invention, the invention'relates to a process involving dispersing particles of a water insoluble organic compound in anaqueous solution of a water soluble heat denaturable protein-thereby applying to and absorbing on the surfaces of the dispersed particles the heat denaturable protein and denaturing the protein on the surfaces of the' particles until it'becornes substantially water insoluble, i.e., cross-linked.
If desired, the dispersion of the water insoluble organic liquid in the aqueous media may be facilitated by using I a water soluble thickening agent, or an agent imparting colloidality to the media. Compounds found very useful as thickening agents include methyl cellulose, hy-
droxyethyl cellulose and sodium carboxymethyl cellulose V and similar compounds known to improve the sus end, ing capacity of aqueous media. Although these colloids are water soluble, they also have some affinity for the Water insoluble organic liquid. ,Thus, thesefcolloids fa cilitate the formation ofv an aqueous dispersion of the organic liquid and have a tendency to concentrate at the interface between the dispersed Water insoluble organic liquid and the continuous aqueous phase. In this way,
the encapsulation is aided.
In many instances sequential coating of the dispersed water insoluble organic liquid particles gives an importantly improved encapsulated material enclosed in concentric shells. In this way, two or more concentric shells composed of water insolubilized proteins may be formed around the water insoluble organic liquid as disclosed herein or concentric shells respectively composed of water insolubilized proteins and cross-linked resins may serve as fillers for any imperfectly formed capsules containing micro cracks. I I
The meaning and significance of the invention will become even more apparent from the following illustrative examples. a
EXAMPLE I I Methyl'Benzoate Encapsulated in Egg'Albumin I Twenty-seven (27) grams of'methyl 'benzoate were added to a solution of ,ZO grams of egg'albumin in' 230 ml. of water at room temperature. The mixture was stirred at approximately 300 r.p.m. and heated on I asuspension in benzene.
ture waspoured into 800 ml. of tap water. Two solid phases formed. One was lighter and the otherhe'avier than the aqueous medium. The less dense solid was washed extensively with methanol. The heavier solid was washed with'water several times by decantation y Both washed solids were dried at 50C. with air'cir vculating through the oven; The odorless mass liberated the odor of methyl benzoate on rubbingthe solid par- 'ti cles against'one another. I
' I EXAMPLE 2 Pinene Encapsulated in Egg Albumin One hundred lOO) grams of pinene were emulsified I I in a solution of'45 grams of egg albumin dissolved in A 900 grams of water. The resulting suspension washeated on a water bath at a rateof 2 to 3 degrees O per minute;
The main batch "of solids was split into' t wo parts One was treated with '30 grams of 37%aqueous form-" aldehyde and the other with 40 grams of 30% glyoxal. Both batches were heated to C. for 15 minutes.
The separation and @drying'steps Were thesame asde scribed in the first"preparation; The resulting dried glyoxal treated material was quite hard and difficultto break by crushing with the fingers. yielded odor on the applicationof frictional forces. Q
EXAMPLIEIISI' Encapsulation of Born'yl Acetate in Bornyl acetate wassuccessfully encapsulated inegg I albumin in weight ratiosfof 1:1 and 2:1 and thereafter treated with formaldehyde by following the procedure I as disclosed in Example 2. An experiment using a3 to 1 ratio had a tendency to oil out. I I s v In these preparations the intial oil dispersion was passed through a colloid mill before theheating step. The final preparationconsisted'of particles of about 1 cm. in diameter. These were broken up in an osterizer as The separated particles were odor free on drying, but
ticle friction. a
- EXAMPLE 4 readily released the odor of bornyl acetate on inter par I V Encapsulation of:-'B 0rnyl Acetate. in Albumin and "Urea- I Formaldehyde Polymer Forty-five; (45) grams of bornyl acetatewere emulsified in a solution of 45 grams of egg albumin dissolved in 900 grams of water. The resulting dispersion was passed through a colloidal mill and the suspension was then heated on a water bath at a rate of 2 to'3 degrees C .'PI' minute. When the temperature reached C., it was held:
[phosphates were dissolved in 25 "grams of an oily-mass I consisting of a perfume oil'prepared from2 0% of each there for ten minutes. After the coagulation was completed, 10'grams of urea, 25. ml. of 35% formaldehyde,
and 1 mol of concentrated hydrochloric acid were'added I in successionand the heating was continued on the water bath until solid urea-formaldehyde resin wasno longer formed. The encapsulated solids were separated in the same .manner as in the preceding examples.
' EXAMPLE .5
Encapsulation of a Mixture of Essential Oils l Formaldehyde and Albumin Two (2) grams. of 'a mixture of mono: and' 'dilauryl Ureaof the following natural oils and synthetic compounds} B-phenyl ethylalcohol, 'geraniol, linalool, altarof 'Rose coagulation beganto set in. r After the temperature reached C;, thereaction mix I When the temperature reached 75 C., it was held there for ten minutes.
A small portion of theformed solids Wcresep'arated by decantation and washed with water and, acetone. This, prod'uct'yielded no pinene odor on crushing.
Both preparations I j 8 and oil of Neroli. This solution was added to a solution of 20 grams of urea in 300 ml. of water, followed by an addition of 50 ml. of 37% formaldehyde. While the above dispersion was being stirred, a solution of 10 grams of alubumin in 100 ml. of water was added dropwise over a period of 2 minutes. The albumin caused the oil to become more finely dispersed and seemed to coagulate around the droplets at room temperature. The preparation was heated in the manner as described in the preceding examples, filtered, Washed with water and isopropanol and dried. Stable capsules of the perfume oil were obtained.
EXAMPLE 6 Encapsulation a Mixture of Essential Oils in Urea- F ormaldelzyde, Albumin and Barium Sulfate Fifty (50) ml. of water was used to dissolve grams of urea, 12.5 grams of 37% aqueous formaldehyde, and 2.5 grams of sodium sulfate. Ten grams of the perfume oil of Example 5 and 1 gram of a mixture of mono and dilauryl phosphates were stirred into the aqueous solution while stirring with a stirrer rotating at 200-300 r.p.m. Then 5 grams of egg albumin in 25 ml. of water was added, and the stirring at 200-300 r.p.m. continued for a half hour. After reaction period induced by heating the reaction mass, the urea formaldehyde resin and the denatured egg albumin were formed into a shell around the oil. A dilute barium chloride solution was then added to form a final coat of barium sulfate with the aqueous sulfate ion present. A very stable encapsulated perfume oil was obtained encased in the cross-linked resins and the coating of barium sulfate.
Colloidal silica or powdered titanium dioxide could be added, at this point in the procedure, in lieu of barium chloride.
EXAMPLE 7 Encapsulation of Normally Solid Volatile Compounds A liquid mixture of 30 grams'of menthol, 10 grams of camphor, and 10 grams of bornyl acetate was stirred and dispersed in 50 grams of 10% methyl cellulose c.p.s.) in water. Fifty grams of an aqueous acidic colloidal solution containing 10% of an urea-formaldehyde prepolymer was added to this dispersion. After stirring, at room temperature, for a half hour, 50 grams of a 10% aqueous egg albumin solution was added and the stirring continued for an equal period. The resulting suspension of capsules may be washed free of mother liquid or used as such for spray-drying, brush or blade application to the surface of paper or other nonwoven or woven fibrous materials.
This preparation can be made odor free by air-drying the filtered, or centrifuged, capsules overnight in an oven kept at 50 to 60 C.
Also, where it is desired to obtain an intimate admixture of the encapsulated material and the carrier, such as in the production of paper for producing a paper handkerchief it is possible to introduce the capsules into the carrier during its manufacture such as by mixing together an aqueous paper pulp and the aqueous suspension of capsules during the processing of the pulp to paper.
A very satisfactory product for the alleviation of colds has been obtained by incorporating the capsules of this example in non-woven paper tissue. Other types of nonwoven fibrous tissue may be used in the same way.
While the preceding examples have related to encapsulating volatile water insoluble organic liquids, especially perfume oils and aromatics, it will be understood that other types of water insoluble liquids, mentioned herein, may be encapsulated by following the same procedure. Also, water soluble heat hardenable proteins may be dissolved in the aqueous medium in place of the egg albumin in equivalent proportions, to encapsulate the water insoluble organic liquids in the other types of denatured proteins derived from the other proteins disclosed above. Likewise, other resins typified by those disclosed hereinbefore, may be substituted for the urea-formaldehyde resins of the examples to modify the denatured protein capsules.
It is apparent from the foregoing discussion that encapsulation and encapsulate has reference to the formation of solid shells or capsules around the dispersed globules of water insoluble organic liquids. As pointed out in the body of the specification and in the specific examples, a dilute suspension of the organic liquid is first formed in an aqueous solution of the heat denaturable protein. These water soluble heat denaturable proteins can concentrate at the oil-water interface where they are insolubilized and formed into a denatured protein shell encapsulating the water insoluble oil by the action of heat or by other methods set out above.
It will be understood the foregoing general description as complemented by the specific examples has served to illustrate the invention and its principles. However, many modifications and variations in the details of the disclosure will occur to those skilled in the art to which the invention appertains and still remain within the principles of the invention and its scope. For instance, the illustrative embodiments of the invention have been concerned primarily with encapsulating water insoluble organic compounds which are liquid at temperatures at which water is liquid and with encapsulating such compounds containing dissolved, or otherwise dispersed therein, additional ingredients which are readily dispersed in the water insoluble organic compounds. It will be apparent, however, that the principles of the invention can be applied to encapsulating ingredients which are more difiicult to disperse in the water insoluble organic liquids. Broadly considered, the principles of this invention can be applied to the encapsulation of any ingredient which has a greater affinity for the water insoluble organic liquid than it has for Water. For example, when the water insoluble organic compound is an oil any ingredient may be kept in dispersion in the dispersed oil phase which is more lipophilic than hydrophilic. Predominantly lipophilic emulsifiers could be used to assist in the dispersion of the substances in the oil phase. The same principle may be used to encapsulate solids which are insoluble both in the oil phase and in the water. For example, the absorption, or coating, of a substance onto the solid particles being dispersed in the oil phase which has an amnity for oil and then dispersing the solid in the oil before it is, in turn, dispersed in the water for encapsulation. This latter principle can be used even to disperse and then encapsulate water soluble solids.
Thus, it will be seen the invention is capable of many modifications as to details and still remain within the scope of the invention as defined in the claims.
What is claimed is:
1. A liquid phase process for encapsulating a water insoluble organic liquid, which comprises dispersing finely divided particles of said liquid and a solution of a water soluble heat denaturable albumin in a body of water, denaturing said albumin by the application of heat until it forms a substantially water insoluble denatured protein coating around said particles while said particles are dispersed in said body of Water thereby encapsulating the particles in a solid shell and separating the encapsulated particles from the body of water.
2. A liquid phase process for encapsulating a water insoluble organic liquid, which comprises dispersing finely divided particles of said liquid and a solution of egg albumin in a body of water, heat denaturing said albumin until it forms a substantially water insoluble denatured egg albumin coating around said particles while said particles are dispersed in said body of water thereby encapsulating the particles in a solid shell and separating the encapsulated particles from the body of water.
'3. A liquid phase process for encapsulating a water insoluble organic liquid, which comprises dispersing finely divided particles of said liquid and a solution of a plurality ofwater soluble cross-linking resin-forming compounds in a' body ofwater, at least one of said resin-forming compounds being a heat denaturable albumin, denaturing said albumin by the application of heat and polymerizing any remaining resin-forming compounds until they deposit solution of a water soluble heat denaturable albumin in v a body of Water, applying heat to said body of water untilsaid albumin deposits a substantially water insoluble heat denatured albumin coating around said particles while said particles are dispersed in said body of Water thereby encapsulating particles in' a solid shell and separating the encapsulated particles from the body Of'WZlIGI". 5. A plurality of small discrete particles of a Water insoluble organic liquid encapsulated in a Water insoluble and substantially impermeable solid shell of a heat denatured albumin. 6. Finely divided particles of a water insoluble aromatic liquid encapsulated in a solid shell of a heat denatured albumin.
7. Finely divided particles of a liquid odoriferous substance encapsulated in a solid shell of a heat denatured egg albumin. g i V V,
8. Finely divided particlesof a perfume oil encapsulated in a solid shell of'a heat denatured egg albumin.
9.' A fibrous tissue having incorporated therein finely divided particles of a Water insoluble but Volatile liquid encapsulated in a heat denatured alb umin shell derived from, a Water soluble albumin.
10'. A plurality of small'discrete, particles ofa water insoluble organic liquid encapsulated in a water insoluble and substantially impermeable composite solid shell coma prising a heat denatured" albumin, "and across-linked imino synthetic resin.
7 11. l A paperltissue having incorporated therein a Water. insoluble but volatile decongestant encapsulatedin. a solid shell of aheat denatured water soluble albumin.
References Cited the file of this patent I IE sT riss PATENTS 2,491,475 Bogin Dec. 20, 1949 2,656,298 Loewe Oct. 20, 1953 2,797,201 Ve'atch et a1. June 25; 1957- 2,80Q,457 Green July 23; 1957 2,800,458 Green July 23,1957 2,870,062 Stanley, et a1. Jan. 20,- 1960 a 2,969,330 Brynko -i Ian, 24, 1961" Katchen et a1. June 2 6, 1962

Claims (1)

1. A LIQUID PHASE PROCESS FOR ENCAPSULATING A WATER INSOLUBLE ORGANIC LIQUID, WHICH COMPRISES DISPERSING FINELY DIVIDED PARTICLES OF SAID LIQUID AND A SOLUTION OF A WATER SOLUBLE HEAT DENATURABLE ALBUMIN IN A BODY OF WATER, DENATURING SAID ALBUMIN BY TE APPLICATION OF HEAT UNTIL IT FORMS A SUBSTANTIALLY WATER INSOLUBLE DENATURED PROTEIN COATING AROND SAID PARTICLES WHILE SAID PARTICLES ARE DISPERSED IN SAID BODY OF WATER THEREBY ENCAPSULATING THE PARTICLES IN A SOLID SHELL AND SEPARATING THE ENCAPSULATED PARTICLES FROM THE BODY OF WATER.
US856379A 1959-12-01 1959-12-01 Encapsulation in natural products Expired - Lifetime US3137631A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US856379A US3137631A (en) 1959-12-01 1959-12-01 Encapsulation in natural products

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US856379A US3137631A (en) 1959-12-01 1959-12-01 Encapsulation in natural products

Publications (1)

Publication Number Publication Date
US3137631A true US3137631A (en) 1964-06-16

Family

ID=25323468

Family Applications (1)

Application Number Title Priority Date Filing Date
US856379A Expired - Lifetime US3137631A (en) 1959-12-01 1959-12-01 Encapsulation in natural products

Country Status (1)

Country Link
US (1) US3137631A (en)

Cited By (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257267A (en) * 1965-05-19 1966-06-21 Harold R Hay Retarding liberation of an additament in forming a fibrous web by embedding the additament in a gel matrix prior to addition to the fibers
US3293114A (en) * 1964-04-03 1966-12-20 Dow Chemical Co Method of forming paper containing gaseous filled spheres of thermoplastic resins and paper thereof
US3384536A (en) * 1965-03-24 1968-05-21 Ncr Co Process for forming fibrous sheets containing limited penetration of additaments within the sheet and sheets thereof
US3406119A (en) * 1965-03-05 1968-10-15 Keuffel & Esser Co Encapsulation
US3490454A (en) * 1966-10-21 1970-01-20 United Merchants & Mfg Catamenial products having a coating of rupturable microcapsules containing medicants
US3515070A (en) * 1968-05-15 1970-06-02 Us Army Chemiluminescent peraminoethylene positioned within a brittle capsule
US3516941A (en) * 1966-07-25 1970-06-23 Minnesota Mining & Mfg Microcapsules and process of making
US3516846A (en) * 1969-11-18 1970-06-23 Minnesota Mining & Mfg Microcapsule-containing paper
US3521637A (en) * 1967-11-28 1970-07-28 Nelson J Waterbury Tampon or similar sanitary napkin containing vitamin a
FR2033293A1 (en) * 1969-02-04 1970-12-04 Oreal
US3623659A (en) * 1969-12-29 1971-11-30 Ncr Co Articles of manufacture containing encapsulated, vaporizable core material
US3663685A (en) * 1968-04-01 1972-05-16 Minnesota Mining & Mfg Biodegradable radioactive particles
US3669899A (en) * 1969-04-29 1972-06-13 Us Plywood Champ Papers Inc Microcapsular opacifier system
US3720579A (en) * 1968-12-23 1973-03-13 Champion Int Corp Fibrous substrates with microcapsular opacifiers
US3816169A (en) * 1969-04-29 1974-06-11 Champion Int Corp Fibrous and non-fibrous substrates coated with microcapsular pacifier system and the production of such coated substrates
US3886084A (en) * 1966-09-29 1975-05-27 Champion Int Corp Microencapsulation system
US3911099A (en) * 1974-01-23 1975-10-07 Defoney Brenman Mayes & Baron Long-acting articles for oral delivery and process
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
USB498208I5 (en) * 1974-08-16 1976-04-13
US3957964A (en) * 1974-01-30 1976-05-18 Colgate-Palmolive Company Dentifrice containing encapsulated flavoring
US3978204A (en) * 1969-02-04 1976-08-31 L'oreal Cosmetic composition containing microencapsulated solvents for nail enamel
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
US4105823A (en) * 1975-11-26 1978-08-08 Wiggins Teape Limited Microcapsules, method for their preparation, and sheet material carrying microcapsules
US4115534A (en) * 1976-08-19 1978-09-19 Minnesota Mining And Manufacturing Company In vitro diagnostic test
US4138362A (en) * 1975-03-24 1979-02-06 Champion International Corporation Formation of microcapsules by interfacial cross-linking, microcapsules produced, and microcapsular dispersion
US4138505A (en) * 1976-10-28 1979-02-06 Blue Wing Corporation Nutrient compositions derived from animal blood solids and process for producing same
WO1979000111A1 (en) * 1977-08-25 1979-03-08 Blue Wing Corp Improved lipid-containing feed supplements and foodstuffs
US4145184A (en) * 1975-11-28 1979-03-20 The Procter & Gamble Company Detergent composition containing encapsulated perfume
US4152272A (en) * 1976-10-29 1979-05-01 The Procter & Gamble Company Fabric conditioning composition
US4169804A (en) * 1976-08-19 1979-10-02 Minnesota Mining And Manufacturing Company Magnetically responsive composite microparticle
US4184495A (en) * 1976-04-07 1980-01-22 Philip Morris, Inc. Process for incorporating flavorant into cellulosic substrates and products produced thereby
US4217369A (en) * 1976-08-09 1980-08-12 The Pillsbury Company Moisture resistant nut-like food composition
US4217370A (en) * 1977-08-25 1980-08-12 Blue Wing Corporation Lipid-containing feed supplements and foodstuffs
US4225620A (en) * 1977-08-26 1980-09-30 Blue Wing Corporation Method for feeding ruminant animals
US4248899A (en) * 1979-02-26 1981-02-03 The United States Of America As Represented By The Secretary Of Agriculture Protected feeds for ruminants
US4273672A (en) * 1971-08-23 1981-06-16 Champion International Corporation Microencapsulation process
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
WO1982001994A1 (en) * 1980-12-11 1982-06-24 Univ Ohio Implants,microbeads,microcapsules,and method for their preparation
US4357259A (en) * 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
US4388352A (en) * 1981-08-03 1983-06-14 Board Of Regents, University Of Washington Method for preparing a controlled release composition
US4396670A (en) * 1980-04-08 1983-08-02 The Wiggins Teape Group Limited Process for the production of microcapsules
EP0093668A1 (en) * 1982-05-04 1983-11-09 Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Microcapsules having a wall of reticulately bound milk proteins, and method for their preparation
WO1984000304A1 (en) * 1982-07-08 1984-02-02 Mitchell Harman Injectible sustained release dosage cylinders
WO1985000011A1 (en) * 1983-06-17 1985-01-03 Univ Miami Microdroplets of water-insoluble drugs
US4514461A (en) * 1981-08-10 1985-04-30 Woo Yen Kong Fragrance impregnated fabric
US4608263A (en) * 1984-09-11 1986-08-26 The Quaker Oats Company Method for making flavored dipeptide sweetened comestible
US4660763A (en) * 1985-09-11 1987-04-28 S. C. Johnson & Son, Inc. Vapor-dispensing device
US4666641A (en) * 1984-06-05 1987-05-19 Universite Paris-Sud (Paris Xi) Preparation of biodegradable microcapsules based on serum albumin
US4715390A (en) * 1985-11-19 1987-12-29 Philip Morris Incorporated Matrix entrapment of flavorings for smoking articles
US4729792A (en) * 1985-11-08 1988-03-08 The Standard Register Company Microcapsules, printing inks and their production
USRE32713E (en) * 1980-03-17 1988-07-12 Capsule impregnated fabric
US4798786A (en) * 1982-05-06 1989-01-17 Stolle Research And Development Corporation Living cells encapsulated in crosslinked protein
EP0349428A1 (en) * 1988-06-30 1990-01-03 Centre National De La Recherche Scientifique (Cnrs) Process for preparing colloidal dispersive protein systems in the shape of nanoparticles
US4898780A (en) * 1985-11-08 1990-02-06 The Standard Register Company Production of microcapsules
US4956129A (en) * 1984-03-30 1990-09-11 Ici Americas Inc. Microencapsulation process
WO1991005482A1 (en) * 1989-10-13 1991-05-02 The Regents Of The University Of California Method to produce unsaturated milk fat and meat from ruminant animals
US5023080A (en) * 1988-06-17 1991-06-11 Basic Bio Systems, Inc. Time release protein
US5055300A (en) * 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
US5074902A (en) * 1990-07-30 1991-12-24 Connick Jr William J Granular products containing fungi encapsulated in a wheat gluten matrix for biological control of weeds
US5132117A (en) * 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
US5143737A (en) * 1989-10-13 1992-09-01 The Regents Of The University Of California Method to produce unsaturated milk fat and meat from ruminant animals
US5383862A (en) * 1990-02-03 1995-01-24 Telemedysis Inc Method and device for enveloping and disinfecting of sharp instruments
US5418010A (en) * 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
US5549903A (en) * 1994-03-03 1996-08-27 Ben Gurion University Of Negev Research & Development Aurthority Microencapsulated composition containing chlorpyrifos or endosulfsan
US5578709A (en) * 1993-03-09 1996-11-26 Middlesex Sciences, Inc. Macromolecular microparticles and methods of production
US5607754A (en) * 1993-11-12 1997-03-04 Kimberly-Clark Corporation Paper web product and method for manufacturing same
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6174514B1 (en) * 1999-04-12 2001-01-16 Fuisz Technologies Ltd. Breath Freshening chewing gum with encapsulations
US20020098573A1 (en) * 1996-10-30 2002-07-25 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20020119199A1 (en) * 1996-08-22 2002-08-29 Indu Parikh Fenofibrate microparticles
US20020172690A1 (en) * 1998-12-22 2002-11-21 Calvert Jay G. Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US20030013693A1 (en) * 1998-02-11 2003-01-16 Rtp Pharma Inc. Method and composition for treatment of inflammatory conditions
US6531156B1 (en) 1994-04-15 2003-03-11 Temple University Aqueous solven encapsulation method, apparatus and microcapsules
US20030049274A1 (en) * 1999-03-08 2003-03-13 Janneke Meulenberg PRRSV vaccines
US6555110B1 (en) 1992-11-16 2003-04-29 The Corporation Of Mercer University Microencapsulated compounds and method of preparing same
US6576264B1 (en) 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US20030152538A1 (en) * 2002-01-16 2003-08-14 George Preti Olfactory adaptation and cross-adapting agents to reduce the perception of body odors
US20030157689A1 (en) * 1998-12-22 2003-08-21 Calvert Jay G. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US6610348B2 (en) 1997-02-17 2003-08-26 Fonterra Tech Limited Gelling agents and gels containing them
US20030175347A1 (en) * 2002-03-14 2003-09-18 Steffier Larry W. Durable film coating compositions having sustained slow-release capability, and methods of use therefor
US20030194442A1 (en) * 2000-09-20 2003-10-16 Skyepharma Canada Inc Insoluble drug particle compositions with improved fasted-fed effects
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
US6682761B2 (en) 2000-04-20 2004-01-27 Rtp Pharma, Inc. Water-insoluble drug particle process
US20040043079A1 (en) * 1992-11-16 2004-03-04 D'souza Martin J. Microencapsulated materials and method of making same
US20040086571A1 (en) * 2001-02-22 2004-05-06 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US20040091535A1 (en) * 2000-09-20 2004-05-13 Skyepharma Canada Inc. Coated tablets
US20040224327A1 (en) * 1996-10-30 2004-11-11 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20050095258A1 (en) * 1999-02-17 2005-05-05 Manuel Campos Fusion proteins comprising carriers that can induce a dual immune response
US6890888B2 (en) 2000-07-03 2005-05-10 Nft Industries, Llc Controlled release agricultural products and processes for making same
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US7041705B2 (en) 1998-08-19 2006-05-09 Jagotec Ag Injectable aqueous dispersions of propofol
US20060183113A1 (en) * 1998-12-22 2006-08-17 Calvert Jay G Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US20060210622A1 (en) * 1999-09-21 2006-09-21 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US20070042000A1 (en) * 1999-04-22 2007-02-22 Mengeling William L Porcine reproductive and respiratory syndrome vaccine based on isolate ja-142
US20070116720A1 (en) * 1998-12-22 2007-05-24 Calvert Jay G Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US20070197670A1 (en) * 2006-02-23 2007-08-23 International Business Machines Corporation Rigidized compliant foam and method for implementing a rigidized compliant foam
US20080233219A1 (en) * 2005-08-31 2008-09-25 Nature Technology Inc. Composition for diet comprising plant essential oil as active ingredient, sheet type composition for diet comprising thereof, percutaneous pharmaceutical agent for diet comprising thereof, and method for producing thereof
US20090078918A1 (en) * 2007-09-25 2009-03-26 Cary Michael Huettner Methods and Structures With Fire Retardant Spheres for Implementing Enhanced Fire Protection
US20090304896A1 (en) * 2006-03-22 2009-12-10 Nestec S.A. Solid product comprising oil-droplets
US20100035276A1 (en) * 2004-06-18 2010-02-11 Regents of of the University of Minnesota Identifying virally infected and vaccinated organisms
WO2010044889A2 (en) 2008-10-16 2010-04-22 Pfizer Inc. Torque teno virus (ttv) isolates and compositions
US20100111984A1 (en) * 2008-09-29 2010-05-06 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US20110059126A1 (en) * 2009-09-02 2011-03-10 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US20110117129A1 (en) * 2008-08-25 2011-05-19 Boehringer Ingelheim Vetmedica, Inc. Vaccine Against Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP PRRS)
US20110195088A1 (en) * 2004-09-21 2011-08-11 Boehringer Ingelheim Vetmedica, Inc. Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use
US20120034337A1 (en) * 2008-12-29 2012-02-09 Friesland Brands B.V. Protein particles and their use in food
US8206746B2 (en) 1996-08-22 2012-06-26 Jagotec Ag Microparticles of water-insoluble substances
WO2012168818A1 (en) 2011-06-08 2012-12-13 Ah Usa 42 Llc Infectious clones of torque teno virus
US8415329B1 (en) 1998-05-29 2013-04-09 Jagotec Ag Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations
US8765142B2 (en) 2011-02-17 2014-07-01 Boehringer Ingelheim Vetmedica Gmbh European PRRSV strain
US8846388B2 (en) 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
US9080143B2 (en) 2005-06-24 2015-07-14 University Of Minnesota PRRS viruses, infectious clones, mutants thereof, and method of use
US20150250227A1 (en) * 2010-03-26 2015-09-10 Philip Morris Usa Inc. Inhibition of sensory irritation during consumption of non-smokeable tobacco products
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
US9315781B2 (en) 2011-07-29 2016-04-19 Boehringer Ingelheim Vetmedica Gmbh Infectious CDNA clone of european PRRS virus and uses thereof
US9566324B2 (en) 2010-11-10 2017-02-14 Zoetis Services Llc North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US9579373B2 (en) 2013-03-15 2017-02-28 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
WO2017165366A1 (en) 2016-03-21 2017-09-28 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
US9944902B2 (en) 2011-02-17 2018-04-17 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of PRRSV
WO2018112169A2 (en) 2016-12-14 2018-06-21 Zoetis Services Llc Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
US10004790B2 (en) 2008-09-29 2018-06-26 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US10010601B2 (en) 2013-12-20 2018-07-03 Boehringer Ingelheim Vetmedica Gmbh PRRS virus variant, European PRRS virus cDNA clone, and uses thereof
US10383934B2 (en) 2010-11-10 2019-08-20 Zoetis Services Llc Effective vaccination against porcine reproductive and respiratory syndrome (PRRS) virus prior to weaning
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
US10849962B2 (en) 2015-10-05 2020-12-01 The Corporation Of Mercer University Method and apparatus for microneedle transdermal delivery
US10881129B2 (en) 2017-08-10 2021-01-05 Wisconsin Alumni Research Foundation Coated egg yolk cores, methods of making and methods of use thereof
WO2022072215A2 (en) 2020-09-29 2022-04-07 Zoetis Services Llc Attenuated porcine epidemic diarrhea virus
WO2022221612A1 (en) 2021-04-16 2022-10-20 Zortis Services Llc Pseudorabies virus vaccine
US11524058B2 (en) 2008-09-29 2022-12-13 The Corporation Of Mercer University Oral dissolving films containing microencapsulated vaccines and methods of making same
US11628208B2 (en) 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2491475A (en) * 1946-03-25 1949-12-20 Parke Davis & Co Enteric capsule
US2656298A (en) * 1948-11-10 1953-10-20 Jacques Loewe Res Foundation Therapeutic product
US2797201A (en) * 1953-05-11 1957-06-25 Standard Oil Co Process of producing hollow particles and resulting product
US2800457A (en) * 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
US2800458A (en) * 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
US2870062A (en) * 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
US2969330A (en) * 1958-06-04 1961-01-24 Ncr Co Oil containing capsules and method of making them
US3041289A (en) * 1959-01-02 1962-06-26 Ncr Co Method of making walled clusters of capsules

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2491475A (en) * 1946-03-25 1949-12-20 Parke Davis & Co Enteric capsule
US2656298A (en) * 1948-11-10 1953-10-20 Jacques Loewe Res Foundation Therapeutic product
US2797201A (en) * 1953-05-11 1957-06-25 Standard Oil Co Process of producing hollow particles and resulting product
US2800457A (en) * 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
US2800458A (en) * 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
US2870062A (en) * 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
US2969330A (en) * 1958-06-04 1961-01-24 Ncr Co Oil containing capsules and method of making them
US3041289A (en) * 1959-01-02 1962-06-26 Ncr Co Method of making walled clusters of capsules

Cited By (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3293114A (en) * 1964-04-03 1966-12-20 Dow Chemical Co Method of forming paper containing gaseous filled spheres of thermoplastic resins and paper thereof
US3406119A (en) * 1965-03-05 1968-10-15 Keuffel & Esser Co Encapsulation
US3384536A (en) * 1965-03-24 1968-05-21 Ncr Co Process for forming fibrous sheets containing limited penetration of additaments within the sheet and sheets thereof
US3257267A (en) * 1965-05-19 1966-06-21 Harold R Hay Retarding liberation of an additament in forming a fibrous web by embedding the additament in a gel matrix prior to addition to the fibers
US3516941A (en) * 1966-07-25 1970-06-23 Minnesota Mining & Mfg Microcapsules and process of making
US3886084A (en) * 1966-09-29 1975-05-27 Champion Int Corp Microencapsulation system
US3490454A (en) * 1966-10-21 1970-01-20 United Merchants & Mfg Catamenial products having a coating of rupturable microcapsules containing medicants
US3521637A (en) * 1967-11-28 1970-07-28 Nelson J Waterbury Tampon or similar sanitary napkin containing vitamin a
US3663685A (en) * 1968-04-01 1972-05-16 Minnesota Mining & Mfg Biodegradable radioactive particles
USRE29066E (en) * 1968-04-01 1976-12-07 Minnesota Mining And Manufacturing Company Biodegradable radioactive particles
US3515070A (en) * 1968-05-15 1970-06-02 Us Army Chemiluminescent peraminoethylene positioned within a brittle capsule
US3720579A (en) * 1968-12-23 1973-03-13 Champion Int Corp Fibrous substrates with microcapsular opacifiers
FR2033293A1 (en) * 1969-02-04 1970-12-04 Oreal
US3978204A (en) * 1969-02-04 1976-08-31 L'oreal Cosmetic composition containing microencapsulated solvents for nail enamel
US3669899A (en) * 1969-04-29 1972-06-13 Us Plywood Champ Papers Inc Microcapsular opacifier system
US3816169A (en) * 1969-04-29 1974-06-11 Champion Int Corp Fibrous and non-fibrous substrates coated with microcapsular pacifier system and the production of such coated substrates
US3516846A (en) * 1969-11-18 1970-06-23 Minnesota Mining & Mfg Microcapsule-containing paper
US3623659A (en) * 1969-12-29 1971-11-30 Ncr Co Articles of manufacture containing encapsulated, vaporizable core material
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
US4273672A (en) * 1971-08-23 1981-06-16 Champion International Corporation Microencapsulation process
US3911099A (en) * 1974-01-23 1975-10-07 Defoney Brenman Mayes & Baron Long-acting articles for oral delivery and process
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
US3957964A (en) * 1974-01-30 1976-05-18 Colgate-Palmolive Company Dentifrice containing encapsulated flavoring
US4001480A (en) * 1974-08-16 1977-01-04 Swift & Company Encapsulation process utilizing microorganisms and products produced thereby
USB498208I5 (en) * 1974-08-16 1976-04-13
US4138362A (en) * 1975-03-24 1979-02-06 Champion International Corporation Formation of microcapsules by interfacial cross-linking, microcapsules produced, and microcapsular dispersion
US4105823A (en) * 1975-11-26 1978-08-08 Wiggins Teape Limited Microcapsules, method for their preparation, and sheet material carrying microcapsules
US4145184A (en) * 1975-11-28 1979-03-20 The Procter & Gamble Company Detergent composition containing encapsulated perfume
US4184495A (en) * 1976-04-07 1980-01-22 Philip Morris, Inc. Process for incorporating flavorant into cellulosic substrates and products produced thereby
US4217369A (en) * 1976-08-09 1980-08-12 The Pillsbury Company Moisture resistant nut-like food composition
US4115534A (en) * 1976-08-19 1978-09-19 Minnesota Mining And Manufacturing Company In vitro diagnostic test
US4169804A (en) * 1976-08-19 1979-10-02 Minnesota Mining And Manufacturing Company Magnetically responsive composite microparticle
US4138505A (en) * 1976-10-28 1979-02-06 Blue Wing Corporation Nutrient compositions derived from animal blood solids and process for producing same
US4152272A (en) * 1976-10-29 1979-05-01 The Procter & Gamble Company Fabric conditioning composition
US4357259A (en) * 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
WO1979000111A1 (en) * 1977-08-25 1979-03-08 Blue Wing Corp Improved lipid-containing feed supplements and foodstuffs
US4217370A (en) * 1977-08-25 1980-08-12 Blue Wing Corporation Lipid-containing feed supplements and foodstuffs
FR2400850A2 (en) * 1977-08-25 1979-03-23 Blue Wing Corp FOOD SUPPLEMENT CONTAINING FAT FOR ANIMAL FEEDING AND PROCESS OF PREPARATION
US4225620A (en) * 1977-08-26 1980-09-30 Blue Wing Corporation Method for feeding ruminant animals
US4248899A (en) * 1979-02-26 1981-02-03 The United States Of America As Represented By The Secretary Of Agriculture Protected feeds for ruminants
USRE32713E (en) * 1980-03-17 1988-07-12 Capsule impregnated fabric
US4396670A (en) * 1980-04-08 1983-08-02 The Wiggins Teape Group Limited Process for the production of microcapsules
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US5332584A (en) * 1980-10-30 1994-07-26 Zeneca Inc. Microcapsules
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
WO1982001994A1 (en) * 1980-12-11 1982-06-24 Univ Ohio Implants,microbeads,microcapsules,and method for their preparation
US4388352A (en) * 1981-08-03 1983-06-14 Board Of Regents, University Of Washington Method for preparing a controlled release composition
US4514461A (en) * 1981-08-10 1985-04-30 Woo Yen Kong Fragrance impregnated fabric
FR2526328A1 (en) * 1982-05-04 1983-11-10 Centre Nat Rech Scient WALL MICROCAPSULES OBTAINED BY CROSSLINKING MILK PROTEINS, AND PROCESS FOR THE PREPARATION THEREOF
EP0093668A1 (en) * 1982-05-04 1983-11-09 Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Microcapsules having a wall of reticulately bound milk proteins, and method for their preparation
US4798786A (en) * 1982-05-06 1989-01-17 Stolle Research And Development Corporation Living cells encapsulated in crosslinked protein
WO1984000304A1 (en) * 1982-07-08 1984-02-02 Mitchell Harman Injectible sustained release dosage cylinders
WO1985000011A1 (en) * 1983-06-17 1985-01-03 Univ Miami Microdroplets of water-insoluble drugs
US4956129A (en) * 1984-03-30 1990-09-11 Ici Americas Inc. Microencapsulation process
US4666641A (en) * 1984-06-05 1987-05-19 Universite Paris-Sud (Paris Xi) Preparation of biodegradable microcapsules based on serum albumin
US4608263A (en) * 1984-09-11 1986-08-26 The Quaker Oats Company Method for making flavored dipeptide sweetened comestible
US4660763A (en) * 1985-09-11 1987-04-28 S. C. Johnson & Son, Inc. Vapor-dispensing device
US4729792A (en) * 1985-11-08 1988-03-08 The Standard Register Company Microcapsules, printing inks and their production
US4898780A (en) * 1985-11-08 1990-02-06 The Standard Register Company Production of microcapsules
US4715390A (en) * 1985-11-19 1987-12-29 Philip Morris Incorporated Matrix entrapment of flavorings for smoking articles
US5023080A (en) * 1988-06-17 1991-06-11 Basic Bio Systems, Inc. Time release protein
US5055300A (en) * 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
EP0349428A1 (en) * 1988-06-30 1990-01-03 Centre National De La Recherche Scientifique (Cnrs) Process for preparing colloidal dispersive protein systems in the shape of nanoparticles
US5143737A (en) * 1989-10-13 1992-09-01 The Regents Of The University Of California Method to produce unsaturated milk fat and meat from ruminant animals
WO1991005482A1 (en) * 1989-10-13 1991-05-02 The Regents Of The University Of California Method to produce unsaturated milk fat and meat from ruminant animals
US5132117A (en) * 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
US5383862A (en) * 1990-02-03 1995-01-24 Telemedysis Inc Method and device for enveloping and disinfecting of sharp instruments
US5074902A (en) * 1990-07-30 1991-12-24 Connick Jr William J Granular products containing fungi encapsulated in a wheat gluten matrix for biological control of weeds
US5418010A (en) * 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
US20090081306A1 (en) * 1992-11-16 2009-03-26 The Corporation Of Mercer University Microencapsulated materials and method of making same
US6555110B1 (en) 1992-11-16 2003-04-29 The Corporation Of Mercer University Microencapsulated compounds and method of preparing same
US7425543B2 (en) 1992-11-16 2008-09-16 The Corporation Of Mercer University Microencapsulated materials and method of making same
US20040043079A1 (en) * 1992-11-16 2004-03-04 D'souza Martin J. Microencapsulated materials and method of making same
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6268053B1 (en) 1993-03-09 2001-07-31 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5578709A (en) * 1993-03-09 1996-11-26 Middlesex Sciences, Inc. Macromolecular microparticles and methods of production
US5607754A (en) * 1993-11-12 1997-03-04 Kimberly-Clark Corporation Paper web product and method for manufacturing same
US5549903A (en) * 1994-03-03 1996-08-27 Ben Gurion University Of Negev Research & Development Aurthority Microencapsulated composition containing chlorpyrifos or endosulfsan
US6531156B1 (en) 1994-04-15 2003-03-11 Temple University Aqueous solven encapsulation method, apparatus and microcapsules
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
US6576264B1 (en) 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US6974593B2 (en) 1995-10-17 2005-12-13 Jagotec Ag Insoluble drug delivery
US20040018229A1 (en) * 1995-10-17 2004-01-29 Henriksen Inge B. Insoluble drug delivery
US8206746B2 (en) 1996-08-22 2012-06-26 Jagotec Ag Microparticles of water-insoluble substances
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US20020119199A1 (en) * 1996-08-22 2002-08-29 Indu Parikh Fenofibrate microparticles
US20040224327A1 (en) * 1996-10-30 2004-11-11 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20040197872A1 (en) * 1996-10-30 2004-10-07 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20060205033A1 (en) * 1996-10-30 2006-09-14 Boehringer Ingelheim Vetmedica Gmbh Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20060240041A1 (en) * 1996-10-30 2006-10-26 Meulenberg Johanna J M PRRSV Vaccines
US8546124B2 (en) 1996-10-30 2013-10-01 Boehringer Ingelheim Vetmedica Gmbh Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20020098573A1 (en) * 1996-10-30 2002-07-25 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US8790656B2 (en) 1996-10-30 2014-07-29 Boehringer Ingelheim Vetmedica Gmbh PRRSV vaccines
US6610348B2 (en) 1997-02-17 2003-08-26 Fonterra Tech Limited Gelling agents and gels containing them
US20030013693A1 (en) * 1998-02-11 2003-01-16 Rtp Pharma Inc. Method and composition for treatment of inflammatory conditions
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US8415329B1 (en) 1998-05-29 2013-04-09 Jagotec Ag Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations
US7097849B2 (en) 1998-08-19 2006-08-29 Jagotec Ag Injectable aqueous dispersions of propofol
US7041705B2 (en) 1998-08-19 2006-05-09 Jagotec Ag Injectable aqueous dispersions of propofol
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US7939106B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US6500662B1 (en) 1998-12-22 2002-12-31 Pfizer Inc. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7618797B2 (en) 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7691389B2 (en) 1998-12-22 2010-04-06 Pfizer Inc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
EP1627919A1 (en) 1998-12-22 2006-02-22 Pfizer Products Inc. An infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US8895025B2 (en) 1998-12-22 2014-11-25 Zoetis Llc Infectious cDNA of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US20060183113A1 (en) * 1998-12-22 2006-08-17 Calvert Jay G Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US8609827B2 (en) 1998-12-22 2013-12-17 Zoetis Llc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US8492132B2 (en) 1998-12-22 2013-07-23 Zoetis Llc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PPRS) virus and uses thereof
US7232680B2 (en) 1998-12-22 2007-06-19 Pfizer Inc. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US20020172690A1 (en) * 1998-12-22 2002-11-21 Calvert Jay G. Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US8481705B2 (en) 1998-12-22 2013-07-09 Zoetis Llc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7132106B2 (en) 1998-12-22 2006-11-07 Pfizer Inc. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US20070116720A1 (en) * 1998-12-22 2007-05-24 Calvert Jay G Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US20030157689A1 (en) * 1998-12-22 2003-08-21 Calvert Jay G. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US20050095258A1 (en) * 1999-02-17 2005-05-05 Manuel Campos Fusion proteins comprising carriers that can induce a dual immune response
US6911206B1 (en) 1999-02-17 2005-06-28 Pfizer Inc. Fusion proteins comprising carriers that can induce a dual immune response
US20030049274A1 (en) * 1999-03-08 2003-03-13 Janneke Meulenberg PRRSV vaccines
US6174514B1 (en) * 1999-04-12 2001-01-16 Fuisz Technologies Ltd. Breath Freshening chewing gum with encapsulations
US20070042000A1 (en) * 1999-04-22 2007-02-22 Mengeling William L Porcine reproductive and respiratory syndrome vaccine based on isolate ja-142
US20110104201A1 (en) * 1999-04-22 2011-05-05 Mengeling William L Porcine Reproductive and Respiratory Syndrome Vaccine Based on Isolate JA-142
US8741309B2 (en) 1999-04-22 2014-06-03 The United States Of America As Represented By The Secretary Of Agriculture Porcine reproductive and respiratory syndrome vaccine based on isolate JA-142
US8747859B2 (en) 1999-04-22 2014-06-10 The United States Of America, As Represented By The Secretary Of Agriculture Porcine reproductive and respiratory syndrome vaccine based on isolate JA-142
US20060210622A1 (en) * 1999-09-21 2006-09-21 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US6682761B2 (en) 2000-04-20 2004-01-27 Rtp Pharma, Inc. Water-insoluble drug particle process
US20090258786A1 (en) * 2000-07-03 2009-10-15 Taylor Pursell Controlled release agricultural products and processes for making the same
US6890888B2 (en) 2000-07-03 2005-05-10 Nft Industries, Llc Controlled release agricultural products and processes for making same
US20050107259A1 (en) * 2000-07-03 2005-05-19 Taylor Pursell Controlled release agricultural products and processes for making same
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
US20040091535A1 (en) * 2000-09-20 2004-05-13 Skyepharma Canada Inc. Coated tablets
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US8703202B2 (en) 2000-09-20 2014-04-22 Jagotec Ag Coated tablets
US20060257494A1 (en) * 2000-09-20 2006-11-16 Michael Vachon Coated tablets
US20030194442A1 (en) * 2000-09-20 2003-10-16 Skyepharma Canada Inc Insoluble drug particle compositions with improved fasted-fed effects
US20040086571A1 (en) * 2001-02-22 2004-05-06 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US20030152538A1 (en) * 2002-01-16 2003-08-14 George Preti Olfactory adaptation and cross-adapting agents to reduce the perception of body odors
US7763238B2 (en) * 2002-01-16 2010-07-27 Monell Chemical Senses Center Olfactory adaptation and cross-adapting agents to reduce the perception of body odors
US8684739B2 (en) 2002-03-14 2014-04-01 Mycone Dental Supply Co., Inc. Durable film coating compositions having sustained slow-release capability, and methods of use therefor
US8668930B2 (en) 2002-03-14 2014-03-11 Mycone Dental Supply Co., Ltd. Durable film coating compositions having sustained slow-release capability, and methods of use therefor
US20030175347A1 (en) * 2002-03-14 2003-09-18 Steffier Larry W. Durable film coating compositions having sustained slow-release capability, and methods of use therefor
US20060198890A1 (en) * 2002-03-14 2006-09-07 Keystone Industries Durable film coating compositions having sustained slow-release capability, and methods of use therefor
US20100035276A1 (en) * 2004-06-18 2010-02-11 Regents of of the University of Minnesota Identifying virally infected and vaccinated organisms
US8399187B2 (en) 2004-06-18 2013-03-19 Regents Of The University Of Minnesota Identifying virally infected and vaccinated organisms
US20110195088A1 (en) * 2004-09-21 2011-08-11 Boehringer Ingelheim Vetmedica, Inc. Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use
US8383131B2 (en) 2004-09-21 2013-02-26 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
US9080143B2 (en) 2005-06-24 2015-07-14 University Of Minnesota PRRS viruses, infectious clones, mutants thereof, and method of use
US20080233219A1 (en) * 2005-08-31 2008-09-25 Nature Technology Inc. Composition for diet comprising plant essential oil as active ingredient, sheet type composition for diet comprising thereof, percutaneous pharmaceutical agent for diet comprising thereof, and method for producing thereof
US20070197670A1 (en) * 2006-02-23 2007-08-23 International Business Machines Corporation Rigidized compliant foam and method for implementing a rigidized compliant foam
US8147896B2 (en) * 2006-03-22 2012-04-03 Nestec S.A. Solid product comprising oil-droplets
US20090304896A1 (en) * 2006-03-22 2009-12-10 Nestec S.A. Solid product comprising oil-droplets
US20090078918A1 (en) * 2007-09-25 2009-03-26 Cary Michael Huettner Methods and Structures With Fire Retardant Spheres for Implementing Enhanced Fire Protection
US20110117129A1 (en) * 2008-08-25 2011-05-19 Boehringer Ingelheim Vetmedica, Inc. Vaccine Against Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP PRRS)
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
US10786558B2 (en) 2008-09-29 2020-09-29 The Corporation Of Mercer University Oral dissolving films
US9149441B2 (en) 2008-09-29 2015-10-06 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US20100111984A1 (en) * 2008-09-29 2010-05-06 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US11524058B2 (en) 2008-09-29 2022-12-13 The Corporation Of Mercer University Oral dissolving films containing microencapsulated vaccines and methods of making same
US10004790B2 (en) 2008-09-29 2018-06-26 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US8969536B2 (en) 2008-10-16 2015-03-03 Zoetis Llc Torque teno virus (TTV) isolates and compositions
US8921535B2 (en) 2008-10-16 2014-12-30 Zoetis Llc Infectious clones of torque teno virus
WO2010044889A2 (en) 2008-10-16 2010-04-22 Pfizer Inc. Torque teno virus (ttv) isolates and compositions
US20110064758A1 (en) * 2008-10-16 2011-03-17 Pfizer Inc. Infectious clones of torque teno virus
US20110150913A1 (en) * 2008-10-16 2011-06-23 Pfizer Inc. Torque teno virus (ttv) isolates and compositions
US20120034337A1 (en) * 2008-12-29 2012-02-09 Friesland Brands B.V. Protein particles and their use in food
US20110059126A1 (en) * 2009-09-02 2011-03-10 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity
US9561270B2 (en) 2009-09-02 2017-02-07 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity
US8846388B2 (en) 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
US20150250227A1 (en) * 2010-03-26 2015-09-10 Philip Morris Usa Inc. Inhibition of sensory irritation during consumption of non-smokeable tobacco products
US11129405B2 (en) 2010-03-26 2021-09-28 Philip Morris Usa Inc. Inhibition of sensory irritation during consumption of non-smokeable tobacco products
US10117453B2 (en) * 2010-03-26 2018-11-06 Philip Morris Usa Inc. Inhibition of sensory irritation during consumption of non-smokeable tobacco products
US11351239B2 (en) 2010-11-10 2022-06-07 Zoetis Services Llc Effective vaccination against porcine reproductive and respiratory syndrome (PRRS) virus prior to weaning
US10383934B2 (en) 2010-11-10 2019-08-20 Zoetis Services Llc Effective vaccination against porcine reproductive and respiratory syndrome (PRRS) virus prior to weaning
US9566324B2 (en) 2010-11-10 2017-02-14 Zoetis Services Llc North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US9944902B2 (en) 2011-02-17 2018-04-17 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of PRRSV
US8765142B2 (en) 2011-02-17 2014-07-01 Boehringer Ingelheim Vetmedica Gmbh European PRRSV strain
US10668144B2 (en) 2011-02-17 2020-06-02 Boehringer Ingelheim Vetmedica Gmbh European PRRSV strain
WO2012168818A1 (en) 2011-06-08 2012-12-13 Ah Usa 42 Llc Infectious clones of torque teno virus
US9315781B2 (en) 2011-07-29 2016-04-19 Boehringer Ingelheim Vetmedica Gmbh Infectious CDNA clone of european PRRS virus and uses thereof
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
US10610581B2 (en) 2012-05-17 2020-04-07 Zoetis Services Llc Effective vaccination against porcine reproductive and respiratory syndrome (PRRS) virus prior to weaning
US11351244B2 (en) 2012-05-17 2022-06-07 Zoetis Services Llc Effective vaccination against porcine reproductive and respiratory syndrome (PRRS) virus prior to weaning
US9579373B2 (en) 2013-03-15 2017-02-28 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
US10639364B2 (en) 2013-12-20 2020-05-05 Boehringer Ingelheim Vetmedica Gmbh PRRS virus variant, european PRRS virus cDNA clone, and uses thereof
US10010601B2 (en) 2013-12-20 2018-07-03 Boehringer Ingelheim Vetmedica Gmbh PRRS virus variant, European PRRS virus cDNA clone, and uses thereof
US10849962B2 (en) 2015-10-05 2020-12-01 The Corporation Of Mercer University Method and apparatus for microneedle transdermal delivery
US11628208B2 (en) 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
WO2017165366A1 (en) 2016-03-21 2017-09-28 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
US11090376B2 (en) 2016-12-14 2021-08-17 Zoetis Services Llc Effective vaccination against European strains of porcine reproductive and respiratory syndrome (PRRS) virus prior to weaning
WO2018112169A2 (en) 2016-12-14 2018-06-21 Zoetis Services Llc Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
US10881129B2 (en) 2017-08-10 2021-01-05 Wisconsin Alumni Research Foundation Coated egg yolk cores, methods of making and methods of use thereof
US11445742B2 (en) 2017-08-10 2022-09-20 Wisconsin Alumni Research Foundation Coated egg yolk cores, methods of making and methods of use thereof
WO2022072215A2 (en) 2020-09-29 2022-04-07 Zoetis Services Llc Attenuated porcine epidemic diarrhea virus
WO2022221612A1 (en) 2021-04-16 2022-10-20 Zortis Services Llc Pseudorabies virus vaccine

Similar Documents

Publication Publication Date Title
US3137631A (en) Encapsulation in natural products
US3755190A (en) Capsule manufacture
US5071706A (en) Oily, free-flowing, microcapsules
EP1531927B1 (en) Process for the preparation of flavor or fragrance microcapsules
US3780195A (en) Encapsulation process
US3585149A (en) Microcapsular opacifier system
EP1196533B1 (en) Improved encapsulated oil particles
JP3616009B2 (en) Flavor and fragrance encapsulation method by controlled water transfer into microcapsules
US3781230A (en) Microcapsular opacifier system
US3201353A (en) Micro-inclusions and method of making same
DE29924358U1 (en) Nano and micro capsules with a polyelectrolyte shell made of several polyelectrolyte layers
Shinde et al. Microencapsulation of eugenol by gelatin-sodium alginate complex coacervation
US3743604A (en) Process for the production of microcapsules
JPH0230736B2 (en)
US4089834A (en) Water-resistant micro-capsular opacifier system and products
JPS63178840A (en) Slowly-releasable microcapsule
JPH06503259A (en) Method for producing collagen particles and their use as carriers for active substrates
US3549555A (en) Encapsulation of lipophilic liquid-in-hydrophilic liquid emulsions
US3816169A (en) Fibrous and non-fibrous substrates coated with microcapsular pacifier system and the production of such coated substrates
JPH021798A (en) Lubricant-containing microcapsule and production thereof
SK et al. Use of microencapsulation in textiles
JP3194768B2 (en) Microcapsule and method for producing the same
US3317434A (en) Method of encapsulating particulate matter by coacervation using gelatins of opposite isoionic ph
US4000345A (en) Substrate having coating thereon comprising microcapsular opacifying agents, and method of preparing same
JPH02280828A (en) Dry powder-like microcapsule particles, carriers carrying them, and manufacture thereof